Literature DB >> 25802077

Chronic kidney disease: Statins in chronic kidney disease: time to move on?

Richard Haynes1, Christoph Wanner2.   

Abstract

Statins reduce the risk of atherosclerotic vascular disease in healthy individuals and those with chronic kidney disease (CKD); however, clinical trials have suggested a minimal effect of statins on CKD progression. The PLANET trials compared the renal effects of rosuvastatin and atorvastatin, but the findings leave many questions unanswered.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25802077     DOI： 10.1038/nrneph.2015.36

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  10 in total

1.  Contrasting Cholesterol Management Guidelines for Adults with CKD.

Authors:  Lisandro D Colantonio; Usman Baber; Maciej Banach; Rikki M Tanner; David G Warnock; Orlando M Gutiérrez; Monika M Safford; Christoph Wanner; George Howard; Paul Muntner
Journal:  J Am Soc Nephrol       Date:  2014-11-13       Impact factor: 10.121

2.  Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.

Authors:  Dick de Zeeuw; Deborah A Anzalone; Valerie A Cain; Michael D Cressman; Hiddo J Lambers Heerspink; Bruce A Molitoris; John T Monyak; Hans-Henrik Parving; Giuseppe Remuzzi; James R Sowers; Donald G Vidt
Journal:  Lancet Diabetes Endocrinol       Date:  2015-02-04       Impact factor: 32.069

3.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson; Karen M Eddleman; Nicole M Jarrett; Ken LaBresh; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

4.  Statin safety: lessons from new drug applications for marketed statins.

Authors:  Terry A Jacobson
Journal:  Am J Cardiol       Date:  2006-02-02       Impact factor: 2.778

Review 5.  KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient.

Authors:  Christoph Wanner; Marcello Tonelli
Journal:  Kidney Int       Date:  2014-02-19       Impact factor: 10.612

6.  Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease.

Authors:  J F Moorhead; M K Chan; M El-Nahas; Z Varghese
Journal:  Lancet       Date:  1982-12-11       Impact factor: 79.321

7.  Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells.

Authors:  James E Sidaway; Robert G Davidson; Fergus McTaggart; Terry C Orton; Robert C Scott; Graham J Smith; Nigel J Brunskill
Journal:  J Am Soc Nephrol       Date:  2004-09       Impact factor: 10.121

8.  Effects of lowering LDL cholesterol on progression of kidney disease.

Authors:  Richard Haynes; David Lewis; Jonathan Emberson; Christina Reith; Lawrence Agodoa; Alan Cass; Jonathan C Craig; Dick de Zeeuw; Bo Feldt-Rasmussen; Bengt Fellström; Adeera Levin; David C Wheeler; Rob Walker; William G Herrington; Colin Baigent; Martin J Landray
Journal:  J Am Soc Nephrol       Date:  2014-05-01       Impact factor: 10.121

9.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Authors:  C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321

10.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Authors:  Colin Baigent; Martin J Landray; Christina Reith; Jonathan Emberson; David C Wheeler; Charles Tomson; Christoph Wanner; Vera Krane; Alan Cass; Jonathan Craig; Bruce Neal; Lixin Jiang; Lai Seong Hooi; Adeera Levin; Lawrence Agodoa; Mike Gaziano; Bertram Kasiske; Robert Walker; Ziad A Massy; Bo Feldt-Rasmussen; Udom Krairittichai; Vuddidhej Ophascharoensuk; Bengt Fellström; Hallvard Holdaas; Vladimir Tesar; Andrzej Wiecek; Diederick Grobbee; Dick de Zeeuw; Carola Grönhagen-Riska; Tanaji Dasgupta; David Lewis; William Herrington; Marion Mafham; William Majoni; Karl Wallendszus; Richard Grimm; Terje Pedersen; Jonathan Tobert; Jane Armitage; Alex Baxter; Christopher Bray; Yiping Chen; Zhengming Chen; Michael Hill; Carol Knott; Sarah Parish; David Simpson; Peter Sleight; Alan Young; Rory Collins
Journal:  Lancet       Date:  2011-06-12       Impact factor: 79.321
  10 in total
  3 in total

Review 1.  Stop chronic kidney disease progression: Time is approaching.

Authors:  Usama Abdel Azim Sharaf El Din; Mona Mansour Salem; Dina Ossama Abdulazim
Journal:  World J Nephrol       Date:  2016-05-06

Review 2.  Diabetic nephropathy: Time to withhold development and progression - A review.

Authors:  Usama A A Sharaf El Din; Mona M Salem; Dina O Abdulazim
Journal:  J Adv Res       Date:  2017-04-21       Impact factor: 10.479

3.  Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin.

Authors:  Marjolein Y A M Kroonen; Jasper Stevens; Dick de Zeeuw; Hiddo J L Heerspink
Journal:  Diabetes Obes Metab       Date:  2019-09-30       Impact factor: 6.577
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.